Eli Lilly's Tasisulam Crashes Out in Late-Stage Trials
By Chris on December 16, 2010
This week, Eli Lilly announced a hold on late-stage trials for its experimental melanoma drug tasisulam due to safety concerns. This was the company’s first statement on the drug since providing seemingly favorable updates in May, and leads us to consider the value of accessing disparate viewpoints on sensitive events where invested parties may do their best to positively spin coverage. Consider the statement by a company representative in Eli Lilly’s May press release:
It’s really no shocker that a company would shine the most favorable light possible on trial results for its drug candidate, but sounds pretty good, right? ‘Encouraging results,’ ‘confirmation’ and ‘right direction’ all carry positive connotations in this context with regards to the company and drug.
However, Recorded Future’s timeline for tasisulam over 2010 shows one particularly notable item just after the corporate announcement when industry blog PharmaGossip cast the drug’s trial results far more negatively.
Later in the year, Eli Lilly’s CEO made a statement on its drug pipeline with the precaution that ‘not all those will make it.’ This preceded a large gap in online coverage for tasisulam before the recent announcement where you can see a thin but high spiking level of momentum (seen in yellow) upon cancellation of the drug’s trial due to safety concerns.
The contrasting, and occasionally extreme, language in both corporate speak and blogger commentary shows the importance of efficient access to invested and non-invested sources.
Want to perform similar analysis on developmental drugs, companies, and more for competitive intelligence or equity research? You can get started with Recorded Future today to leverage the same set of tools used in this post.